Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CD74 | P04233 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.35 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30850470 | 1.00 | ALDH1A1 (0.46) | ALDH1A1CALM1MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL132209 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CALM1MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL27072915 | 0.70 | CALM1 (0.55) | ALDH1A1CALM1MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL2129775 | 0.68 | ALDH1A1 (0.52) | ALDH1A1CALM1MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL21986304 | 0.67 | HPGD (0.50) | ALDH1A1SMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL3819703 | 0.67 | BCL2 (0.42) | ALDH1A1CALM1HPGD | |
| SCHEMBL8040113 | 0.66 | ALDH1A1 (0.44) | ALDH1A1CALM1MAOBRAB9ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16246102 | 0.66 | HPGD (0.49) | ALDH1A1SMN1; SMN2L3MBTL1HPGD | |
| SCHEMBL11330543 | 0.66 | KCNH2 (0.62) | ALDH1A1CALM1MAOBRAB9ASMN1; SMN2 | |
| SCHEMBL31167981 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071270-A1 | ON-SEQUENCER IMAGING FLOWCELL REUSE | ILLUMINA, INC. (US) | 2026-03-12 | — | — | US | claimed |
| US-6740655-B2 | 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA | PFIZER INC | 2004-05-25 | — | — | US | claimed |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PFIZER PRODUCTS INC. | 2003-07-31 | — | — | US | claimed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | claimed |
| EP-1140784-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | claimed |
| WO-2000037422-A2 | ION CHANNEL MODULATING AGENTS | NEUROSEARCH A/S (DK) | 2000-06-29 | — | — | WO | claimed |
| US-20260071270-A1 | ON-SEQUENCER IMAGING FLOWCELL REUSE | ILLUMINA, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4678764-A2 | NANOPARTICLE WITH SINGLE SITE FOR TEMPLATE POLYNUCLEOTIDE ATTACHMENT | ILLUMINA, INC. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4081657-B1 | NANOPARTICLE WITH SINGLE SITE FOR TEMPLATE POLYNUCLEOTIDE ATTACHMENT | ILLUMINA INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250236865-A1 | METHODS FOR CAPTURING LIBRARY DNA FOR SEQUENCING | ILLUMINA, INC. | 2025-07-24 | — | — | US | disclosed |
| EP-4587588-A1 | NANOPARTICLE WITH POLYNUCLEOTIDE BINDING SITE AND METHOD OF MAKING THEREOF | ILLUMINA, INC. (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4186529-B1 | IMPROVED ANTIBODY-PAYLOAD CONJUGATES (APCS) PREPARED BY SITE-SPECIFIC CONJUGATION UTILIZING GENETIC CODE EXPANSION | VERAXA BIOTECH GMBH (DE) | 2025-07-09 | — | — | EP | disclosed |
| EP-1252157-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2001057025-A1 | PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-0219852-B1 | CHARTREUSIN DERIVATIVES, SALTS THEREOF, ANTITUMOROUS COMPOSITIONS CONTAINING THE SAME, AND PROCESSES FOR PRODUCING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5064945-A | Antitumor Agents | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1991-11-12 | — | — | US | disclosed |
| US-4927919-A | ANTITUMOR AGENTS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0231244-A1 | 6-ALKYLIDENE PENEMS | BEECHAM GROUP PLC (GB) | 1987-08-12 | — | — | EP | disclosed |
| WO-1987000525-A1 | 6-ALKYLIDENE PENEMS | BEECHAM GROUP P.L.C. (GB) | 1987-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260071270-A1 | ON-SEQUENCER IMAGING FLOWCELL REUSE | NT5C3B, SMCHD1, NT5C2 | ALDH1A1 3823/4885CALM1 2117/4885MAOB 1891/4885 |
| US-20030144300-A1 | Pyrimidine carboxamides useful as inhibitors of pde4 isozymes | PDE12, PDE4A, PDE4B | ALDH1A1 978/4885CALM1 2276/4885MAOB 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.